SNY - Regeneron/Sanofi's Largest Selling Drug Dupixent Scores FDA Approval For Infants With Esophagus Inflammation | Benzinga
Thursday, the FDA approved Regeneron Pharmaceutical Inc (NASDAQ:REGN) / Sanofi SA’s (NASDAQ:SNY) Dupixent (dupilumab) for the treatment of pediatric patients aged 1 to 11 years, weighing at least 15 kg, with eosinophilic esophagitis (EoE).
EoE is a recognized chronic allergic/immune condition of the esophagus. It is a disease in which eosinophils (a type of white blood cell) build up in the esophagus.
EoE may experience heartburn, vomiting, abdominal discomfort, trouble swallowing, food refusal, and failure to thrive.
Dupixent is now the first and only medicine approved in the U.S. specifically indicated to treat these patients.
Also Read: Sanofi/Regeneron’s Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder.